Providing Today's Patients with Medicines of the Future.
Staff
2017-2019 Net Profit CAGR
Current Brands of Products
Innovative Product Candidates
Covering Class III Hospitals
Covering Other Hospitals & Medical Institutions
On July 21, 2025, Simcere Zaiming, an innovative oncology-focused subsidiary of Simcere Pharmaceutical Group (2096.HK), announced that the U.S. Food a...
On July 08, 2025, the new drug application (NDA) of the innovative drug Rademikibart, jointly developed by the Simcere（2096.HK） and Connect Biopharma,...
On June 20, 2025, Simcere Pharmaceutical (2096.HK) announced that QUVIVIQ® (generic name: Daridorexant Hydrochloride Tablets), an anti-insomni...
Shanghai, China, June 18, 2025 — Simcere Zaiming, an innovative oncology-focused subsidiary of Simcere Pharmaceutical Group (2096.HK) today announc...